Comparison · NCT06115681-eeaf8dd7
DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Steroid Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Steroid Therapy. Trial comparisons, record NCT06115681-eeaf8dd7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06115681-eeaf8dd7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00364 | 0.000642 | 0.0203 | wilson | |
| Risk in group 2 | 0.000897 | 0.000158 | 0.00506 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00274 | -0.00239 | 0.0194 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4.05 | 0.254 | 64.6 | log | |
| Odds ratio, group 1 over group 2 | 4.07 | 0.254 | 65.2 | log | |
| Number needed to treat, for one more participant with the outcome on DDLPS Patients With 1L Treatment at Index Date (Cohort 1) than on DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | 365 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DDLPS Patients With 1L Treatment at Index Date (Cohort 1) | Patients with unresectable locally advanced or metastatic differentiated liposarcoma (DDLPS) who received at least one line of systemic antineoplastic treatment by the end of cohort identification period (index date = start date of first line (1L) treatment). | 1 | 275 | OG000 |
| Group 2 | DDLPS Patients Without 1L Treatment at Index Date (Cohort 2) | Patients with DDLPS who have not initiated 1L systemic antineoplastic treatment by the end of cohort identification period (index date = date of initial DDLPS diagnosis during cohort identification period). Patients initiated 1L treatment afterwards or patients received adjuvant and/or neoadjuvant therapy only through follow-up will be included in Cohort 2. | 1 | 1,115 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Cohort 1, Cohort 2: Number of Patients With Treatments Classified as Concurrent Steroid Therapy
- Description
- Number of patients who received treatments with drugs classified as concurrent steroid therapy for both cohorts is reported.
- Time frame
- At index date and during follow-up, up to 10 years
- Population
All patients diagnosed with dedifferentiated liposarcoma (DDLPS) who met the inclusion criteria of having at least 2 documented clinical visits in National Anti-Tumor Drug Surveillance System (NATDSS) in China on or after January 1, 2013 and aged ≥18 years at initial diagnosis.
Source ClinicalTrials.gov
Trial
- Title
- Real-world Study of Dedifferentiated Liposarcoma Patients in China
- NCT number
- NCT06115681
- Phases
- Conditions
- Dedifferentiated Liposarcoma
- Interventions
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2025-07-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT06115681?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT06115681-eeaf8dd7